You are here

Efaproxiral NDA to be Reviewed by FDA Advisory Committee

WESTMINSTER, Colo., March 12 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. announced today that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) plans to review the company's investigational radiation sensitizer, RSR13 (efaproxiral), on May 3, 2004. Information regarding the ODAC panel is now available via the FDA Hotline at 1-800-741-8138 and will soon be posted to the Federal Register.

On February 2, 2004, the FDA accepted for priority review the company's New Drug Application (NDA 21-661) seeking approval to market RSR13 as an adjunct to whole brain radiation therapy for the treatment of patients with brain metastases originating from breast cancer. The FDA has established a target date of June 4, 2004 to take action on the NDA.

"We welcome the additional review and insight the FDA's outside scientific advisors will provide at the ODAC hearing," said Michael E. Hart, President and CEO of Allos Therapeutics, Inc. "The recent acceptance for priority review of our NDA exemplifies our ongoing cooperative efforts with the FDA."

About RSR13 (efaproxiral)

RSR13 (efaproxiral) is the first synthetic small molecule designed to "sensitize" hypoxic (oxygen-deprived) areas of tumors prior to radiation therapy by facilitating the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells, and increasing the level of oxygen in tumors. The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy in the treatment of cancer. By increasing tumor oxygenation at the time of treatment, RSR13 (efaproxiral) has the potential to enhance the efficacy of standard radiation therapy. Unlike chemotherapeutics or other radiation sensitizers, RSR13 (efaproxiral) does not have to cross the blood brain barrier or enter the tumor to be effective.

Source: Allos Therapeutics, Inc.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival